Biotech firm DSciLab has raised 100 million yuan ($14 million) in an angel financing round led by Fosun Health Capital, the first venture capital fund set up by Chinese pharmaceutical group Fosun Pharma, per a press release.
The fund aims to invest in early-stage companies developing innovative drug products and technologies.
Local investment firm Shanghai Creation Investment also joined the round.
Incubated by Fosun Health Capital in June 2022, DSciLab specialises in the research and development of lipid-based delivery systems and messenger ribonucleic acid (mRNA) therapeutics.
CHINA DEAL MONITOR
DealStreetAsia has also compiled a table listing all prominent venture capital transactions in Greater China from April 29 – May 5, 2024.
